I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The  company  Laboratoire  HRA  Pharma  submitted  on  2  October  2002  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Lysodren,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  23  July  2002,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr Gonzalo Calvo Rojas 
Co-Rapporteur: 
Prof Silvio Garattini 
Licensing status: 
Lysodren  has  been  given  a  Marketing  Authorisation  in  Brazil  on  25  July  1988,  in  Canada  on 
14 December  1978,  in  Hong-Kong  on  20 June 1989,  in  Malaysia  on  15  December  1986,  in  South 
Korea on 9 October 2001, in the USA on 8 July 1970 and in Singapore (approved SIN3544P). 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 November 2002. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members on  29  January 
2003. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 28 
January 2003. 
During  the  meeting  on  18-19  March  2003  the  CPMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 19 March 2003. 
The company submitted the responses to the consolidated list of questions on 27 July 2003. 
The Rapporteurs circulated the response assessment report on the company’s responses to the 
list of questions to all CPMP Members on 22 September 2003. 
During the meeting on 21-22 October 2003 the CPMP agreed on a List of Outstanding Issues to 
be addressed in writing by the applicant. 
The applicant submitted answers to the List of Outstanding Issues on 7 November 2003. 
The  Joint  Rapporteur/Co-Rapporteur  Assessment  Report  on  the  applicant’s  responses  was 
circulated on 5 December 2003. 
During  the  meeting  on  21-22  October  2003  the  CPMP  agreed  on  a  List  of  Questions  to  be 
answered by TAG in Oncology on 17 November 2003. 
Answers to the questions were given by the TAG in Oncology on 17 November 2003. 
During the meeting on 18-20 November 2003, the CPMP adopted a Second List of Outstanding 
Issues. The second List of Outstanding Issues was sent to the Applicant on 20 November 2003. 
The  Joint  Rapporteur/Co-Rapporteur  Assessment  Report  on  the  applicant’s  responses  to  the 
Second List of Outstanding Issues was circulated on 9 January 2004. 
During the meeting on 20-21 January 2004 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Lysodren  on  21  January  2004.  The  applicant  provided  a  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 18 January 2004. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 28 April 2004. 
CPMP/712/04 
1/2 
EMEA 2004 
II  GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION 
1.  Manufacturing Authorisation Holder and inspection status 
Manufacturer(s) of the active substance 
Mitotane 
ISP Chemical Inc. 
1979 Atlas Street 
Colombus 
OHIO 43228 
USA 
Manufacturer(s) of the finished product 
Bristol-Myers Squibb Spa 
Via del Murillo Km 2800 
04010 Sermoneta (Latina) 
ITALY  
Manufacturer responsible for batch release 
Bristol-Myers Squibb 
Via del Murillo Km 2800 
04010 Sermoneta 
ITALY  
Manufacturer responsible for import and batch release in the European Economic Area 
Bristol-Myers Squibb 
Via del Murillo Km 2800 
04010 Sermoneta 
ITALY 
2. 
Conditions or restrictions regarding supply and use 
Medicinal product subject to restricted medical prescription. 
CPMP/712/04 
2/2 
EMEA 2004 
 
 
 
 
